Concepedia

Risk-adapted induction and consolidation therapy in adults with de novo AML aged =�60�years: results of a prospective multicenter trial

Gerhard Heil, J Krauter, A. Raghavachar, Lothar Bergmann, D. Hoelzer, Walter Fiedler, Michael L�bbert, L. Noens, Günter Schlimok, R. Arnold,

Annals of Hematology · 2004 · 56 citations · 22 references

DOI

Concepts

References

22

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver et al. · Blood · 1998 · 2.6K citations · Full text

, , +12

Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461)

John C. Byrd · Blood · 2002 · 1.6K citations

, , +16

Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study

Marilyn L. Slovak, Kenneth J. Kopecky, Peter A. Cassileth et al. · Blood · 2000 · 1.6K citations

, , +10

Intensive Postremission Chemotherapy in Adults with Acute Myeloid Leukemia

Robert J. Mayer, Roger B. Davis, Charles A. Schiffer et al. · New England Journal of Medicine · 1994 · 1.4K citations · Full text

, , +13

Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Clara D. Bloomfield, David Lawrence, John C. Byrd et al. · PubMed · 1998 · 696 citations

, , +15